Recombinant Capital Presents
ALLICENSE 2003
BRINGING KNOWLEDGE TO PARTNERSHIPS
April 29 & 30, 2003
Westin St. Francis Hotel, San Francisco, CA
Program Agenda
Tuesday, April 29
8:00 – 8:30
Welcoming Remarks & Conference Overview: Bringing Knowledge to Partnerships
· Mark G. Edwards, Managing Director, Recombinant Capital
8:30 – 9:00
Discovery Collaborations – Where Do We Go From Here?
· Dr. George Scangos, Chief Executive Officer, Exelixis
9:00 – 9:30
Leveraging Alliances to Keep in the Forefront of Drug Development & Innovation
· Dr. Robert Armstrong, Vice President, Discovery Chemistry Research and Technology, Eli Lilly and Company
Morning Break 9:30 – 10:00
10:00 – 12:00
Session 1: Shaping the Pharmaceutical Company of the Future: What Role Will Alliances Play?
· Session Chair: Patty Martin, Executive Director, Alliance Management, Eli Lilly and Company
· Dr. Thomas Hofstaetter, Senior Vice President, Corporate Development, Aventis
· Tom Joyce, Senior Director of Marketing, Neurocrine Biosciences
· Dr. Herbert S. Ormsbee, Senior Director, Licensing & Development, Pfizer Inc.
· Michael D. Step, Vice President, Corporate Development, Amylin Pharmaceuticals, Inc.
· Barbara Yanni, Chief Licensing Officer, Merck & Co.
12:00 – 1:30
Luncheon hosted by
1:30 – 3:00
Session 2: Building to Last – Flexibility & Clarity in Pharma/Biotech Alliances
· Session Chair: Arlene M. Morris, President & CEO, Clearview Projects
· Jack M. Anthony, Senior Vice President, Business and Commercial Development, Tularik
· Tom Finn, Vice President, Worldwide Strategic Planning, Procter & Gamble
· Patrick Verheyen, Vice President, Business Development, Johnson & Johnson
Afternoon Break 3:00 - 3:30
3:30 – 5:30
Session 3: Asset-Based Alliances: A Roundtable Discussion of Creative Deal Structures
· Session Chair: Clifford J. Stocks, Vice President, Business Development, ICOS Corporation
· Tamar Howson, Senior Vice President, Corporate and Business Development, Bristol-Myers Squibb
· Barbara Kosacz, Head, Life Sciences Practice, Cooley Godward
· Joseph McCracken, Vice President, Business & Commercial Development, Genentech
· Gwen A. Melincoff, Vice President, Business Development, Adolor
6.00 - 10.00 pm
ALLICENSE 2003 BREAKTHROUGH ALLIANCE AWARDS DINNER
........................................................................
Wednesday, April 30
8:00 – 8:30
Partnering with the NIH – A Time of New Growth & Challenges
· Dr. Mark L. Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health
8:30 – 9:00
Putting Genomics to Work in Clinical Development of Drug Candidates
· Brad Margus, Chief Executive Officer, Perlegen
9:00 – 9:30
Co-Development & Commercialization Alliances – Taking Partnerships to the Next Level
· Rick E. Winningham, Chief Executive Officer, Theravance
Morning Break 9:30 – 10:00
10:00 – 12:00
Session 4: Integrating Alliances on a Worldwide Basis
· Session Chair: Dr. Samir Master, Global Head, Search and Evaluation, Global Business Development and Licensing, Novartis Pharmaceuticals
· Scott Foraker, Vice President, Licensing, Amgen
· Dr. Robert Lipshutz, Senior Vice President, Corporate Development, Affymetrix
· Dr. Ulrich Koch, Head of Corporate Business Development, Schering AG
· R. Christopher Seaton, Senior Vice President, Global Licensing, Bayer Corporation
Luncheon 12:00 – 1:30
1:30 – 3:00
Session 5: Taking Stock of the Seed-Corn of Innovation
· Session Chair: Lita L. Nelsen, Director, Technology Licensing Office, Massachusetts Institute of Technology
· Katharine Ku, Director, Office of Technology Licensing, Stanford
· Timothy J. Reckart, Senior Vice President & General Counsel, Research Corporation Technologies
Afternoon Break 3:00 – 3:30
3:30 – 5:00
Session 6: Biotech & Partnering: If You Build It, Will They Come? A Roundtable Discussion
· Session Chair: Mark G. Edwards, Managing Director, Recombinant Capital
· Brian G. Atwood, Managing Director, Versant Ventures
· Chris Ehrlich, Venture Partner, InterWest Partners
· Michael Lytton, General Partner, Oxford Bioscience Partners
· Nicholas Simon III, General Partner, MPM Capital
5:00 – 6:00
Cocktail Reception
|